BENITIONSClinical Trial Intelligence

SPYRAL HTN-ON MED Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode Renal Denervation System

不适用 已完成 NCT02439775

适应症Hypertension, Vascular Diseases, Cardiovascular Diseases
分期不适用
申办方Medtronic Vascular
状态已完成
受试者人数337 人
干预(药物)Symplicity Spyral™ multi-electrode renal denervation system, Sham Procedure
开始日期2015年7月22日
完成日期2022年8月18日
结果公布日2023年9月15日

摘要

The purpose of this study is to test the hypothesis that renal denervation decreases blood pressure and is safe when studied in the presence of up to three standard antihypertensive medications.

Change in Systolic Blood Pressure as Measured by 24-hour Ambulatory Blood Pressure Monitoring (ABPM)

From baseline to 6 months post-procedure · mm Hg

Renal Denervation-6.5 ± 10.7 mm Hg
Sham Procedure-4.5 ± 10.3 mm Hg

Acute and Chronic Safety by Evaluating Incidence of Major Adverse Events

From Baseline to 1 month post-procedure (6 months for new renal artery stenosis) · Participants

Renal Denervation204 Participants
Sham Procedure130 Participants
Renal Denervation2 Participants
Sham Procedure1 Participants

在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文

同一适应症的其他试验

全部试验

本页整理自 ClinicalTrials.gov 的公开数据,不构成医疗建议,也不构成投资建议。请务必咨询专业医师。